Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (PDE11A) is a dual-specificity enzyme that catalyzes the hydrolysis of both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into their inactive 5'-monophosphate forms. By regulating the intracellular concentrations of these critical second messengers, PDE11A plays a key role in signal transduction pathways governing endocrine function, spermatogenesis, cell proliferation, and neural processes such as social memory formation and mood stabilization. The enzyme is expressed in a tissue-restricted manner, with notable expression in the prostate, testis, adrenal gland, and the hippocampus of the brain. Mutations and dysregulation of PDE11A are clinically linked to endocrine disorders, including Cushing's disease, isolated micronodular adrenocortical disease, and various tumors such as testicular and prostate cancers. In the central nervous system, age-related increases in PDE11A expression in the hippocampus lead to liquid-liquid phase separation (LLPS) and the formation of filamentous structures known as 'ghost axons,' which contribute to age-related cognitive decline. While there are currently no approved selective PDE11A inhibitors, the approved PDE5 inhibitor tadalafil exhibits significant off-target inhibition of PDE11A. Recent drug discovery efforts have focused on developing highly selective, brain-penetrant PDE11A inhibitors (such as the SMQ and MLG series) to reverse LLPS, reduce neuroinflammation, and treat cognitive disorders like Alzheimer's disease and age-related dementia.
Inhibition of cAMP and cGMP hydrolysis
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (PDE11A).